Harrow, Inc.

Contributing Author

Recent Articles by Harrow, Inc.

Aug-20	Harrow Announces IHEEZO Data in Patient-Reported Discomfort Following Intravitreal Injections HROW GlobeNewswire
Aug-10	Harrow Announces Second Quarter 2026 Financial Results HROW GlobeNewswire
Aug-06	Harrow Acquires Global Rights to TYRVAYA, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease HROW GlobeNewswire
Jul-27	Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026 HROW GlobeNewswire
Jul-20	Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ / AMELIVU), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026 HROW GlobeNewswire
Jul-20	Harrow Highlights Growing Clinical Evidence Supporting IHEEZO and BYOOVIZ at ASRS 2026 Annual Meeting HROW GlobeNewswire
Jul-01	Harrow Announces Commercial Launch of BYOOVIZ in the United States HROW GlobeNewswire
Jun-10	Harrow Re-Launches VERKAZIA (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare HROW +7.29% GlobeNewswire
May-27	Harrow to Present at William Blair's 46th Annual Growth Stock Conference HROW GlobeNewswire
May-11	Harrow Announces First Quarter 2026 Financial Results HROW HROW -23.69% GlobeNewswire
Apr-27	Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026 HROW GlobeNewswire
Apr-16	Harrow Announces the Issuance of J-Code for IOPIDINE 1% HROW GlobeNewswire
Mar-24	Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030 HROW GlobeNewswire
Mar-24	Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth HROW GlobeNewswire
Mar-18	Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting HROW GlobeNewswire
Mar-04	Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference HROW GlobeNewswire
Mar-03	Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication HROW -27.96% GlobeNewswire
Mar-02	Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance HROW GlobeNewswire
Feb-18	Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026 HROW GlobeNewswire
Feb-17	Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack Kits HROW +5.98% GlobeNewswire
Feb-02	Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270-$280 Million, Marking Another Year of Strong Growth HROW +9.67% GlobeNewswire
Nov-24	Harrow to Present at Two Investor Conferences in December HROW GlobeNewswire
Nov-18	Harrow Announces Closing of Acquisition of Melt Pharmaceuticals HROW GlobeNewswire
Nov-10	Harrow Announces Third Quarter 2025 Financial Results HROW HROW +13.47% GlobeNewswire
Oct-27	Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025 HROW GlobeNewswire
Oct-06	ImprimisRx Announces Leadership Changes HROW -7.20% GlobeNewswire
Sep-26	Harrow to Acquire Melt Pharmaceuticals HROW GlobeNewswire
Sep-25	Harrow Launches Harrow Access for All (HAFA) HROW GlobeNewswire
Sep-15	Harrow Announces Agenda and Speakers for Investor & Analyst Day HROW +8.63% GlobeNewswire
Sep-08	Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030 HROW +7.52% GlobeNewswire
Sep-08	Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030 HROW +7.52% GlobeNewswire
Aug-11	Harrow Announces Second-Quarter 2025 Financial Results HROW GlobeNewswire
Aug-06	Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference HROW GlobeNewswire
Jul-29	Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025 HROW GlobeNewswire

Harrow, Inc.

Recent Articles by Harrow, Inc.

Upgrade your Finviz experience